NEETPGAI
FeaturesBlogComparePricing
Log inStart Free
NEETPGAI

AI-powered NEET PG preparation platform. Master all 19 subjects with adaptive MCQs, AI tutoring, and spaced repetition.

Product

  • Features
  • Subjects
  • Previous Year Questions
  • Compare
  • Pricing
  • Blog

Features

  • Adaptive MCQ Practice
  • AI Tutor
  • Mock Tests
  • Spaced Repetition

Resources

  • Blog
  • Study Guides
  • NEET PG Updates
  • Contact & support

Legal

  • Privacy Policy
  • Terms of Service

Stay updated

© 2026 NEETPGAI. All rights reserved.
    Subjects/Pathology/Chronic Leukemias
    Chronic Leukemias
    easy
    microscope Pathology

    Which feature best distinguishes chronic myeloid leukemia (CML) from chronic lymphocytic leukemia (CLL)?

    A. Elevated leukocyte count (>50,000/μL)
    B. Lymphocytosis on peripheral blood smear
    C. Presence of Philadelphia chromosome t(9;22)
    D. Splenomegaly on clinical examination

    Explanation

    Distinguishing CML from CLL

    Philadelphia Chromosome — The Gold Standard Discriminator
    Key Point
    The Philadelphia chromosome t(9;22) resulting in the BCR-ABL1 fusion gene is pathognomonic for CML and is present in >95% of cases. This is the single most reliable feature that separates CML from CLL.
    Comparison Table: CML vs CLL
    Table
    FeatureCMLCLL
    Philadelphia chromosome t(9;22)Present (>95%)Absent
    Cell lineageMyeloidLymphoid (B-cell)
    Peripheral bloodMyeloid left shift, basophilia, eosinophiliaMature lymphocytes, smudge cells
    SplenomegalyVery common (90%)Common (50–60%)
    Leukocyte countOften >50,000/μLVariable, often modest
    Median age at diagnosis50–60 years>70 years
    BCR-ABL1 transcriptBCR-ABL p210 (most common)Absent
    Why Philadelphia Chromosome Is Superior
    1. 1.
      Cytogenetic hallmark: Present in nearly all CML cases; virtually never in CLL.
    2. 2.
      Molecular target: Drives pathogenesis via constitutive tyrosine kinase activity.
    3. 3.
      Diagnostic criterion: WHO classification mandates BCR-ABL1 positivity for CML diagnosis.
    4. 4.
      Therapeutic relevance: Tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) are standard of care for CML but not CLL.
    Clinical Pearl
    A patient with myeloid leukocytosis and Philadelphia chromosome positivity is CML until proven otherwise. Conversely, a lymphoid leukocytosis with Philadelphia chromosome would be extremely rare and would represent a CML in lymphoid blast crisis or a rare BCR-ABL1+ lymphoma.
    High-YieldNEET PG
    FISH or PCR for BCR-ABL1 is now the standard diagnostic method; karyotyping alone may miss variant translocations. Always order BCR-ABL1 testing in any chronic leukemia with myeloid predominance.

    Robbins 10e Ch 13

    Practice similar questions

    Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.

    Start Practicing Free More Pathology Questions

    Join our NEET PG community

    Daily MCQs, study tips, and topper strategies on Telegram.

    Join on Telegram →